Prevymis (letermovir) - Merck (MSD)
Harmacokinetics of Letermovir in Pediatric Recipients Following Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) (ChiCTR) - Jun 6, 2025 - P=N/A | N=10 | Not yet recruiting | Sponsor: Blood Disease Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences); Institute of Hematology &a 
New trial • Bone Marrow Transplantation • Pediatrics • Transplantation
https://www.chictr.org.cn/showproj.html?proj=269184
 
Jun 6, 2025
 
Prev Next